CAN
IOVA icon

Claraphi Advisory Network’s Iovance Biotherapeutics IOVA Stock Holding History

Claraphi Advisory Network’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,218
Closed -$214K – 333
2021
Q2 		$214K Sell
8,218
-9,099
-53% -$237K 0.06% 294
2021
Q1 		$548K Buy
17,317
+228
+1% +$9.45K 0.15% 145
2020
Q4 		$793K Buy
+17,089
New +$678K 0.22% 97

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Claraphi Advisory Network's IOVA Position: Q3 2021 in Review

Claraphi Advisory Network sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 8,218 shares — an estimated $214K sold.

Claraphi Advisory Network first reported a position in IOVA in Q4 2020 and held it in 3 quarters. The position peaked at $793K in Q4 2020. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Claraphi Advisory Network reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Claraphi Advisory Network sold 8,218 Iovance Biotherapeutics shares in Q3 2021, an estimated $214K.
  • Claraphi Advisory Network first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 3 quarters.
  • Claraphi Advisory Network's Iovance Biotherapeutics position peaked at $793K in Q4 2020.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Claraphi Advisory Network's 13F filing for Q3 2021, filed 15 Nov 2021.